Buy Aurobindo Pharma, target price Rs 880: Motilal Oswal
The brokerage raised the companys EPS estimate for FY20/FY21 by 4.4 per cent/9 per cent, and expects a 9 per cent earnings CAGR over FY20–22, led by new launches and increased market share in key markets,